Drug Profile
Research programme: CDX bi-specific antibodies - Hemogenyx
Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; HemoGenix
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Stem cell engraftment